A single-center, prospective, self-controlled study on the efficacy and safety of Suoyang Gujing Pills in the treatment of male premature ejaculation (kidney deficiency syndrome)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071963

Enrollment

Unknown

Registered

2023-05-30

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary premature ejaculation

Interventions

test group:suoyang gujing pills

Eligibility

Sex/Gender

All

Age

23 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1: Meet the diagnostic criteria for premature ejaculation 2: It meets the diagnostic criteria of kidney deficiency syndrome of premature ejaculation 3: Age 23-50 years old (including threshold value) 4: Sexual frequency =1 times/week 5: The erectile function was normal, with a score of > 21 on the International Erectile Function Scale (IIEF-5) 6: Subjects agreed not to use any other premature ejaculation medications during the study period, including 5-HT reuptake inhibitors (SSris), local anesthetics, type 5 phosphodiesterase inhibitors (PDE5i), alpha1 adrenergic blockers, Chinese herbal medicines (including decoction, proprietary Chinese medicine), or devices used to treat PE 7: Subjects voluntarily sign informed consent

Exclusion criteria

Exclusion criteria: 1: There are premature ejaculation caused by high penile head sensitivity, genetic variation, prostatitis, thyroid disease, etc 2: Patients with diabetes, nervous system diseases, cardiovascular diseases and serious diseases of heart, liver, kidney and other major organs 3: People with a history of mental illness (e.g. major depression, major anxiety) 4: Suspected or confirmed history of alcohol or drug abuse 5: Have taken a drug similar to the trial drug in the last 2 weeks 6: Allergic to Suoyang Gujing pills 7: Participants who have participated or are participating in other clinical trials within 3 months 8: Those considered unsuitable for inclusion by researchers

Design outcomes

Primary

Measure	Time frame
Incubation period of vaginal ejaculation;	—

Secondary

Measure	Time frame
PE diagnostic tool;TCM syndrome score;safety;	—

Countries

China

Contacts

Public ContactHaisong Li

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

lihs369@sina.com+86 10 8401 3276

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026